1. Home
  2. PRLD vs CEE Comparison

PRLD vs CEE Comparison

Compare PRLD & CEE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRLD
  • CEE
  • Stock Information
  • Founded
  • PRLD 2016
  • CEE 1990
  • Country
  • PRLD United States
  • CEE Germany
  • Employees
  • PRLD N/A
  • CEE N/A
  • Industry
  • PRLD Medicinal Chemicals and Botanical Products
  • CEE Finance Companies
  • Sector
  • PRLD Health Care
  • CEE Finance
  • Exchange
  • PRLD Nasdaq
  • CEE Nasdaq
  • Market Cap
  • PRLD 73.7M
  • CEE 72.9M
  • IPO Year
  • PRLD 2020
  • CEE N/A
  • Fundamental
  • Price
  • PRLD $1.05
  • CEE $12.07
  • Analyst Decision
  • PRLD Strong Buy
  • CEE
  • Analyst Count
  • PRLD 2
  • CEE 0
  • Target Price
  • PRLD $4.50
  • CEE N/A
  • AVG Volume (30 Days)
  • PRLD 611.2K
  • CEE 22.0K
  • Earning Date
  • PRLD 02-13-2025
  • CEE 01-01-0001
  • Dividend Yield
  • PRLD N/A
  • CEE 3.86%
  • EPS Growth
  • PRLD N/A
  • CEE N/A
  • EPS
  • PRLD N/A
  • CEE N/A
  • Revenue
  • PRLD $3,000,000.00
  • CEE N/A
  • Revenue This Year
  • PRLD N/A
  • CEE N/A
  • Revenue Next Year
  • PRLD N/A
  • CEE N/A
  • P/E Ratio
  • PRLD N/A
  • CEE N/A
  • Revenue Growth
  • PRLD N/A
  • CEE N/A
  • 52 Week Low
  • PRLD $0.80
  • CEE $7.80
  • 52 Week High
  • PRLD $6.80
  • CEE $10.32
  • Technical
  • Relative Strength Index (RSI)
  • PRLD 45.27
  • CEE 56.74
  • Support Level
  • PRLD $0.98
  • CEE $11.65
  • Resistance Level
  • PRLD $1.43
  • CEE $12.32
  • Average True Range (ATR)
  • PRLD 0.12
  • CEE 0.38
  • MACD
  • PRLD -0.02
  • CEE 0.09
  • Stochastic Oscillator
  • PRLD 14.14
  • CEE 82.14

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

About CEE The Central and Eastern Europe Fund Inc. (The)

CENTRAL & EASTERN EUROPE FUND, INC. is a closed-end management investment company. The Fund's objective is to seek long-term capital appreciation. It invests in the equity or equity-linked securities of issuers domiciled in Central and Eastern Europe.

Share on Social Networks: